Todd M. Sanger
Eli Lilly and Company
92 Papers
1.3K Citations
Todd M. Sanger is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Olanzapine & Placebo. The author has an hindex of 30, co-authored 92 publications. Previous affiliations of Todd M. Sanger include University of California, Los Angeles.
Chat about Author
Papers
Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial
Charles M. Beasley,Gary D. Tollefson,Pierre Tran,Winston Satterlee,Todd M. Sanger,Susan H. Hamilton +5 more
TL;DR: The most common treatment-emergent adverse events included somnolence, agitation, asthenia, and nervousness.
780
Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: A double-blind, randomized, placebo-controlled trial
J.S. Street,W. Scott Clark,K.S. Gannon,Jeffrey L. Cummings,Frank P. Bymaster,Roy N. Tamura,Steven J. Mitan,Deborah L. Kadam,Todd M. Sanger,Todd M. Sanger,Peter D. Feldman,Gary D. Tollefson,Alan Breier +12 more
TL;DR: Low-dose olanzapine (5 and 10 mg/d) was significantly superior to placebo and well tolerated in treating agitation/aggression and psychosis in this population of patients with AD.
Efficacy of olanzapine in acute bipolar mania: A double-blind, placebo-controlled study
Mauricio Tohen,T. Jacobs,S. L. Grundy,Susan L. McElroy,Michael C. Banov,Philip G. Janicak,Todd M. Sanger,R.C. Risser,Fan Zhang,V. Toma,Judith Francis,Gary D. Tollefson,Alan Breier +12 more
TL;DR: Olanzapine demonstrated greater efficacy than placebo in the treatment of acute bipolar mania and was generally well tolerated.
579
Olanzapine Versus Placebo in the Treatment of Acute Mania
Mauricio Tohen,Todd M. Sanger,Susan L. McElroy,G.D. Tollefson,K. N. R. Chengappa,D. G. Daniel,Frederick Petty,Franca Centorrino,R. Wang,S. L. Grundy,M. Greaney,T. Jacobs,S.R. David,V. Toma +13 more
TL;DR: The olanzapine group experienced significantly greater mean mean scores than the placebo group in the treatment of acute mania, and the primary efficacy measure was defined as a change from baseline to endpoint in total score on the Young Mania Rating Scale.
551
Olanzapine versus placebo in the treatment of acute mania
TL;DR: Recent work from this laboratory has shown that acute depletion of plasma tryptophan in Bipolar patients stable on long-term Lithium prophylaxis does not cause any change in suicidality ratings suggesting that Lithium's beneficial effects on suicide are not mediated via S-HT.
356